CLINICAL OUTCOMES Protégé GPS Self-expanding Peripheral and Biliary Stent

DURABILITY ILIAC¹ was conducted to confirm the safety and effectiveness of primary stenting using the EverFlex™ and Protégé™ GPS™ self-expanding stent systems for the treatment of lesions in the common and external iliac arteries. 

• 75 subjects enrolled
• ≥ 50% stenosis, restenosis or occlusion
• Target lesion length ≤ 10 cm
• Target vessel diameter ≥ 4.5 mm and ≤ 11.0 mm

Results of DURABILITY ILIAC study with Protégé GPS Stent:

• 45/75 patients received a Protégé GPS stent
• Nine-month MAE rate of 2.2%
  • 2.2% clinically drive TLR
  • 0% periprocedural death
  • 0% in-hospital MI
  • 0% amputation of treated limb
• Nine-month primary patency rate of 97.7%